These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35757899)

  • 1. Hybrid closed-loop therapy with a first-generation system increases confidence and independence in diabetes management in youth with type 1 diabetes.
    Roberts A; Fried L; Dart J; de Bock M; Fairchild J; King B; Ambler GR; Cameron F; McAuley SA; Keech AC; Jenkins A; O Neal DN; Davis EA; Jones TW; Abraham MB;
    Diabet Med; 2022 Sep; 39(9):e14907. PubMed ID: 35757899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
    Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
    Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lived experience of older adults with type 1 diabetes using closed-loop automated insulin delivery in a randomised trial.
    Kubilay E; Trawley S; Ward GM; Fourlanos S; Grills CA; Lee MH; MacIsaac RJ; O'Neal DN; O'Regan NA; Sundararajan V; Vogrin S; Colman PG; McAuley SA
    Diabet Med; 2023 Apr; 40(4):e15020. PubMed ID: 36468784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
    Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
    Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use.
    Berget C; Akturk HK; Messer LH; Vigers T; Pyle L; Snell-Bergeon J; Driscoll KA; Forlenza GP
    Diabetes Obes Metab; 2021 Sep; 23(9):2048-2057. PubMed ID: 34010499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and Their Parents.
    Cobry EC; Hamburger E; Jaser SS
    Diabetes Technol Ther; 2020 Nov; 22(11):794-800. PubMed ID: 32212971
    [No Abstract]   [Full Text] [Related]  

  • 7. Real world use of hybrid-closed loop in children and young people with type 1 diabetes mellitus-a National Health Service pilot initiative in England.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    Diabet Med; 2023 Feb; 40(2):e15015. PubMed ID: 36424877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Patient Experience of Long-Term Hybrid Closed-Loop Insulin Pump Use.
    Wang LR; Malcolm J; Arnaout A; Humphrey-Murto S; LaDonna KA
    Can J Diabetes; 2021 Dec; 45(8):750-756.e3. PubMed ID: 33958309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world lived experience of older adults with type 1 diabetes after an automated insulin delivery trial.
    Kubilay E; Trawley S; Ward GM; Fourlanos S; Colman PG; McAuley SA
    Diabet Med; 2024 Apr; 41(4):e15264. PubMed ID: 38073128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case series of a hybrid closed-loop system used in pregnancies in clinical practice.
    Polsky S; Akturk HK
    Diabetes Metab Res Rev; 2020 Mar; 36(3):e3248. PubMed ID: 31758630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives.
    Hood KK; Laffel LM; Danne T; Nimri R; Weinzimer SA; Sibayan J; Bailey RJ; Schatz D; Bratina N; Bello R; Punel A; Calhoun P; Beck RW; Bergenstal RM; Phillip M
    Diabetes Technol Ther; 2021 Dec; 23(12):857-861. PubMed ID: 34270328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol.
    de Bock M; McAuley SA; Abraham MB; Smith G; Nicholas J; Ambler GR; Cameron FJ; Fairchild JM; King BR; Geelhoed EA; Davis EA; O'Neal DN; Jones TW;
    BMJ Open; 2018 Aug; 8(8):e020275. PubMed ID: 30104309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of real-life clinical outcomes in Australian youth with type 1 diabetes on hybrid closed-loop therapy: A retrospective study.
    Vijayanand S; Stevenson PG; Broad E; Davis EA; Taplin CE; Jones TW; Abraham MB
    J Paediatr Child Health; 2022 Sep; 58(9):1578-1583. PubMed ID: 35642299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study.
    Forlenza GP; Vigers T; Berget C; Messer LH; Lal RA; Basina M; Maahs DM; Hood K; Buckingham B; Wilson DM; Wadwa RP; Driscoll KA; Pyle L
    Diabetes Technol Ther; 2022 Mar; 24(3):157-166. PubMed ID: 34780306
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting.
    Barnard KD; Wysocki T; Thabit H; Evans ML; Amiel S; Heller S; Young A; Hovorka R;
    Diabet Med; 2015 May; 32(5):601-8. PubMed ID: 25615888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.
    Messer LH; Forlenza GP; Sherr JL; Wadwa RP; Buckingham BA; Weinzimer SA; Maahs DM; Slover RH
    Diabetes Care; 2018 Apr; 41(4):789-796. PubMed ID: 29444895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.